Radiofrequency ablation for early-stage kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tracks people with early-stage kidney cancer (tumors smaller than 4 cm) who are treated with radiofrequency ablation, a procedure that uses heat to destroy cancer cells. The goal is to see how well this treatment works in real-world practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a kidney tumor smaller than 4 cm (stage T1a).
- The tumor has been confirmed as cancer by a biopsy (done before or within 30 days of the procedure).
- You do not have other health conditions that would make the procedure unsafe.
- You are in generally good health (able to do daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing or burning (ablating) the main kidney tumor helps people with advanced kidney cancer who are already doing well on immunotherapy. Researchers want to see if combining local treatment with ongoing immunotherapy can improve outcomes.
This study tests whether closely monitoring small kidney tumors (less than 4 cm) with regular imaging is a safe and effective option for people who cannot or choose not to have immediate treatment. It involves a biopsy at the start to confirm the tumor type.
This study is testing whether high-dose radiation therapy can safely treat kidney cancer that has spread to a few spots in the body, either when it is first found or when it grows during standard drug treatment. The goal is to see if this approach is effective and well-tolerated.
This trial tests a treatment called Y90 radioembolization for people with early-stage kidney cancer who cannot have surgery or ablation. Tiny radioactive beads are delivered through a catheter to the tumor's blood supply to destroy it from the inside.
This trial tests a focused, high-dose radiation treatment (SABR) for kidney tumors that are too risky to remove with surgery or where surgery was declined. It may help shrink the tumor while limiting damage to surrounding tissue.
This trial tests a precise type of radiation therapy for small, early-stage kidney tumors that cannot be surgically removed or are at high risk for surgery. It aims to offer an alternative treatment with fewer side effects.
Hear when a new Renal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.